Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib
Open Access
- 17 March 2025
- journal article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2471022
Abstract
Highly pathogenic avian influenza A viruses (HPAIV) pose a significant threat to both animal and human health. These viruses have the potential to cause severe respiratory and systemic infections in birds and several mammalian species. The recent global outbreak of the H5N1 clade 2.3.4.4b spread in wild and domestic birds is now considered to be a panzoonosis. Spillover events in dairy cattle farms in the U.S. have highlighted the urgent need for effective antiviral therapies, especially in view of human infections. This study investigates the selective MEK1/2 inhibitor zapnometinib (ZMN) as a potential antiviral agent against HPAIVs. Our in vitro experiments demonstrate that ZMN significantly impairs viral replication across multiple HPAIV strains, including H5N1 clade 2.3.4.4b in cell lines and primary bronchial epithelial cells. The mechanism of action is based on the nuclear retention of newly produced viral ribonucleoprotein complexes (vRNP), when the MEK/ERK/RSK1 kinase cascade is inhibited. We furthermore could show, that ZMN not only acts antiviral in a standalone treatment but has synergistic potential when used in combination with direct-acting antivirals like oseltamivir or baloxavir. Therefore, ZMN treatment offers a promising strategy for future antiviral development.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB1009B02)
- Deutsche Forschungsgemeinschaft (Lu477/23-2)
- Deutsche Forschungsgemeinschaft (CRU342P06)
- “Innovative Medical Research” of the University of Münster Medical School (I-SC122105)
- “Innovative Medical Research” of the University of Münster Medical School (I-SC212302)
- Ministry of Culture and Science of the State of NRW, Germany (76.06.04-20/2024-6626)
- Ministry of National Education
This publication has 61 references indexed in Scilit:
- The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responsesCellular and Molecular Life Sciences, 2022
- Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2Protein & Cell, 2020
- Zoonotic Influenza and Human Health—Part 2: Clinical Features, Diagnosis, Treatment, and Prevention StrategiesCurrent Infectious Disease Reports, 2018
- Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudinsHepatology, 2015
- MEK/ERK activation plays a decisive role in yellow fever virus replication: Implication as an antiviral therapeutic targetAntiviral Research, 2014
- Influenza Pathobiology and Pathogenesis in Avian Species2014
- Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitroAntiviral Research, 2013
- Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infectionAntiviral Research, 2012
- Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivoAntiviral Research, 2011
- Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivoAntiviral Research, 2011